# Experiments and Analyses

> These are declarative verification plans derived from abstract-level claims. The provided input is a review abstract, not a report of original experiments; exact quantitative outcomes are not available from provided input and are intentionally absent here.

## E01: Verify anti-amyloid immunotherapy effect in early-stage Alzheimer's disease
- **Verifies**: C01
- **Setup**:
  - Population: Early-stage Alzheimer's disease patients.
  - Intervention: Anti-amyloid monoclonal antibodies such as lecanemab and donanemab.
  - Comparator: Placebo, standard care, or another appropriate control.
  - Data source: Not available from provided input.
- **Procedure**:
  1. Identify randomized or controlled evidence for the named anti-amyloid therapies.
  2. Compare cognitive-decline trajectories between treated and control groups.
  3. Assess whether the treatment effect supports the review's qualitative efficacy claim.
- **Metrics**: Cognitive decline measures; exact instruments not available from provided input.
- **Expected outcome**: Treated early-stage patients decline more slowly than comparator patients.
- **Baselines**: Comparator/control treatment; details not available from provided input.
- **Dependencies**: none

## E02: Verify symptomatic and functional role of cholinesterase inhibitors and memantine
- **Verifies**: C02
- **Setup**:
  - Population: Patients with mild, moderate to severe dementia.
  - Intervention: Cholinesterase inhibitors and/or memantine.
  - Comparator: Placebo, no treatment, or alternative symptomatic care.
  - Data source: Not available from provided input.
- **Procedure**:
  1. Review clinical evidence for symptomatic treatment in the stated dementia severities.
  2. Compare symptom and functional trajectories under treatment versus comparator.
  3. Determine whether the evidence supports continued standard-treatment status.
- **Metrics**: Symptom scales and functional outcomes; exact measures not available from provided input.
- **Expected outcome**: Treated patients show better symptomatic or functional stability than comparator patients.
- **Baselines**: Comparator/control treatment; details not available from provided input.
- **Dependencies**: none

## E03: Verify biomarker framework contribution to staging and treatment planning
- **Verifies**: C03
- **Setup**:
  - Population: Patients across the Alzheimer's disease spectrum.
  - Diagnostic inputs: Fluid and imaging biomarkers.
  - Treatment output: Individualized treatment plans.
  - Data source: Not available from provided input.
- **Procedure**:
  1. Assess whether fluid and imaging biomarkers improve stage assignment.
  2. Determine whether stage assignment changes treatment selection or care planning.
  3. Compare biomarker-informed plans against non-biomarker clinical assessment.
- **Metrics**: Staging precision, treatment-plan stratification, clinical appropriateness; exact measures not available from provided input.
- **Expected outcome**: Biomarker-informed frameworks produce more precise staging and more individualized treatment planning.
- **Baselines**: Clinical assessment without biomarker integration.
- **Dependencies**: none

## E04: Verify multimodal non-pharmacological care integration
- **Verifies**: C04
- **Setup**:
  - Population: Patients across the Alzheimer's disease spectrum and caregivers.
  - Interventions: Lifestyle modifications, cognitive training, caregiver support.
  - Comparator: Pharmacotherapy-only care or usual care.
  - Data source: Not available from provided input.
- **Procedure**:
  1. Identify evidence for each named non-pharmacological component.
  2. Assess whether integrated care plans improve patient or caregiver outcomes relative to usual care.
  3. Determine whether multimodal personalization changes treatment fit across disease stages.
- **Metrics**: Patient function, cognition, quality of life, caregiver outcomes; exact measures not available from provided input.
- **Expected outcome**: Integrated multimodal care improves or stabilizes patient/caregiver outcomes relative to less comprehensive care.
- **Baselines**: Usual care or pharmacotherapy-only care.
- **Dependencies**: E02, E03

## E05: Verify implementation constraints and evidence maturation needs
- **Verifies**: C05
- **Setup**:
  - Population: Patients eligible or potentially eligible for Alzheimer's disease therapies.
  - Domains: Patient selection, treatment-related side effects, access to therapies, ongoing trials, real-world evidence.
  - Data source: Not available from provided input.
- **Procedure**:
  1. Review criteria used to select patients for disease-modifying and symptomatic therapy.
  2. Summarize treatment-related side-effect evidence and monitoring implications.
  3. Assess access barriers and real-world evidence gaps.
  4. Determine whether ongoing trials or observational evidence address these constraints.
- **Metrics**: Eligibility clarity, safety burden, access measures, evidence-gap resolution; exact measures not available from provided input.
- **Expected outcome**: Patient selection, side effects, access, and evidence maturation remain active constraints requiring further refinement.
- **Baselines**: Current practice without refined selection, safety, access, or real-world evidence updates.
- **Dependencies**: E01, E03, E04
